Locking malaria parasites into red blood...UK researchers headed by Michael Blackman have found out that a proteolytic cascade regulates release of merozoites of the human malaria parasite Plasmodium falciparum from host red blood cells. … more ➔
PharmaMar in licence deal with Seattle Gen...Spanish specialist for sea-derived synthetic oncology drugs, PharmaMar SA, has inked a licence agreement with US antibody drug conjugate (ADC) company Seattle Genetics Inc. PharmaMar will provide fully-synthetic … more ➔
Roche to pay US$1.9bn for Flatiron HealthIn a strategic acquisition, Roche has completed its capabilities to use Big data to build new business cases in digital diagnostics solutions and personalised healthcare. The pharma major agreed to pay … more ➔
Santhera licenses CF drug from Polyphor Santhera Pharmaceuticals has licenced the inhaled neutrophil eleastase blocker POL6014 from Polyphor Ltd for CHF6.5m upfront and CHF121m in potential milestones. more ➔
AML: Sorafenib boosts graft-versus-leukemi...Co-administration of an allogenic blood stem cell transplant and sorafenib cured AML patients refractive to chemotherapy and stem cell transplants alone, oncologists report in Nature Medicine. more ➔
Poxel in €506m diabetes deal with Roivan...Poxel S.A. is advancing its proof-of-concept type 2 diabetes programme imeglimin (PXL008) into Phase III studies in the US an the EU by means of a licence deal with Swiss Roivant Sciences GmbH. more ➔
Pieris inks US$1.2bn immuno-oncology deal... Anticalin developer Pieris and Antibody-drug conjugate specialist Seattle Genetics have agreed to co-develop three bispecific cancer drugs using Seattle Genetics cancer targets and Pieris co-stimulatory … more ➔
DMD drug aids heart failure patients Italfarmaco SpAs Givinostat, a small molecule histone deacetylase (HDAC) inhibitor in clinical testing against several forms muscular dystrophies, is also an option to treat heart failure with preserved … more ➔
New target could minimise transplant risksGerman researchers have identified a target to switch off intestinal acute graft-versus-host disease (GVHD), which occurs in about 50% of leukemia patients that have been given a allogeneic hematopoietic … more ➔
EU General Court rejects industrys confi...The European Medicines Agency (EMA) has won a landmark battle about the amount of data from clinical dossiers that may be made public. The European Court of Justics (EJC) rejected the demand of three … more ➔